Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Eculizumab Is an Effective Treatment for Atypical Hemolytic Uremic Syndrome in Patients with or without Identified Genetic Complement Mutations or Complement Factor H Auto-Antibodies.

Samhar I. Al-Akash, Timothy H. J. Goodship, MD, Richard J. H. Smith, MD, Christophe M. Legendre, MD, Christoph Licht, MD, Petra Muus, MD, PhD, Camille L. Bedrosian, MD, Veronique Frémeaux-Bacchi, PhD, Chantal Loirat, MD

Blood (2012) 120 (21): 2085.

https://doi.org/10.1182/blood.V120.21.2085.2085

Published: 2012

Journal Articles

Eculizumab (ECU) Safety and Efficacy in Atypical Hemolytic Uremic Syndrome (aHUS) Patients with Long Disease Duration and Chronic Kidney Disease (CKD): 2-Year Results

Christoph Licht, MD, Petra Muus, MD, PhD, Christophe M. Legendre, MD, Kenneth W. Douglas, MD, Maryvonne Hourmant, MD, Yahsou Delmas, MD, Maria Herthelius, MD, Antonella Trivelli, MD, Timothy H. J. Goodship, MD, Camille L. Bedrosian, MD, Chantal Loirat, MD

Blood (2012) 120 (21): 985.

https://doi.org/10.1182/blood.V120.21.985.985

Published: 2012

Journal Articles

A novel hybrid CFH/CFHR3 gene generated by a microhomology-mediated deletion in familial atypical hemolytic uremic syndrome

Nigel J. Francis, Bairbre McNicholas, Atif Awan, Mary Waldron, Donal Reddan, Denise Sadlier, David Kavanagh, Lisa Strain, Kevin J. Marchbank, Claire L. Harris, Timothy H. J. Goodship

Blood (2012) 119 (2): 591–601.

https://doi.org/10.1182/blood-2011-03-339903

Published: 2012

Includes: Supplemental data

Journal Articles

Eculizumab Is An Effective Long-Term Treatment In Patients with Atypical Hemolytic Uremic Syndrome (aHUS) Previously Receiving Chronic Plasma Exchange/Infusion (PE/PI): Extension Study Results,

Christoph Licht, MD, Petra Muus, MD, PhD, Christophe Legendre, MD, Kenneth W Douglas, MD, Maryvonne Hourmant, MD, Yahsou Delmas, MD, Maria Herthelius, MD, Antonella Trivelli, MD, Timothy H. J. Goodship, MD, Camille L Bedrosian, MD, Chantal Loirat, MD

Blood (2011) 118 (21): 3303.

https://doi.org/10.1182/blood.V118.21.3303.3303

Published: 2011

Journal Articles

Association of factor H autoantibodies with deletions of CFHR1 , CFHR3 , CFHR4 , and with mutations in CFH , CFI , CD46 , and C3 in patients with atypical hemolytic uremic syndrome

Iain Moore, Lisa Strain, Isabel Pappworth, David Kavanagh, Paul N. Barlow, Andrew P. Herbert, Christoph Q. Schmidt, Scott J. Staniforth, Lucy V. Holmes, Roy Ward, Lynn Morgan, Timothy H. J. Goodship, Kevin J. Marchbank

Blood (2010) 115 (2): 379–387.

https://doi.org/10.1182/blood-2009-05-221549

Published: 2010

Journal Articles

Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome

Blood (2008) 112 (13): 4948–4952.

https://doi.org/10.1182/blood-2008-01-133702

Published: 2008

Includes: Supplemental data

Journal Articles

Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome

Celia J. Fang, Veronique Fremeaux-Bacchi, M. Kathryn Liszewski, Gaia Pianetti, Marina Noris, Timothy H. J. Goodship, John P. Atkinson

Blood (2008) 111 (2): 624–632.

https://doi.org/10.1182/blood-2007-04-084533

Published: 2008

Includes: Supplemental data

NARROW

Eculizumab Is an Effective Treatment for Atypical Hemolytic Uremic Syndrome in Patients with or without Identified Genetic Complement Mutations or Complement Factor H Auto-Antibodies.

Eculizumab (ECU) Safety and Efficacy in Atypical Hemolytic Uremic Syndrome (aHUS) Patients with Long Disease Duration and Chronic Kidney Disease (CKD): 2-Year Results

A novel hybrid CFH/CFHR3 gene generated by a microhomology-mediated deletion in familial atypical hemolytic uremic syndrome

Eculizumab Is An Effective Long-Term Treatment In Patients with Atypical Hemolytic Uremic Syndrome (aHUS) Previously Receiving Chronic Plasma Exchange/Infusion (PE/PI): Extension Study Results,

Association of factor H autoantibodies with deletions of CFHR1 , CFHR3 , CFHR4 , and with mutations in CFH , CFI , CD46 , and C3 in patients with atypical hemolytic uremic syndrome

Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome

Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome

Email alerts

ASH Publications

American Society of Hematology

Eculizumab Is an Effective Treatment for Atypical Hemolytic Uremic Syndrome in Patients with or without Identified Genetic Complement Mutations or Complement Factor H Auto-Antibodies.

Eculizumab (ECU) Safety and Efficacy in Atypical Hemolytic Uremic Syndrome (aHUS) Patients with Long Disease Duration and Chronic Kidney Disease (CKD): 2-Year Results

A novel hybrid CFH/CFHR3 gene generated by a microhomology-mediated deletion in familial atypical hemolytic uremic syndrome

Eculizumab Is An Effective Long-Term Treatment In Patients with Atypical Hemolytic Uremic Syndrome (aHUS) Previously Receiving Chronic Plasma Exchange/Infusion (PE/PI): Extension Study Results,

Association of factor H autoantibodies with deletions of CFHR1 , CFHR3 , CFHR4 , and with mutations in CFH , CFI , CD46 , and C3 in patients with atypical hemolytic uremic syndrome

Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome

Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only